Worth separating two things that the opening post runs together.
SURMOUNT-4 used a randomised withdrawal design: everyone titrated, then those on maintenance were randomised to continue or placebo. Continuation maintained effect; withdrawal was followed by regain. The finding is robust but it says nothing about a lower effective maintenance dose, because that was not studied.
Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.
Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.
Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.
Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.
Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.
Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.
Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.
Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.
Read the full topic (123 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Tirzepatide storage and stability: what is published versus what is assumed
On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read…
|
+17 | 21 | 17k | 12d |
|
What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version
Asking directly, because I could not find a straight answer: What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version Comparing PIONEER 6 ( N Engl J Med ,…
|
+48 | 52 | 609 | 10mo |
|
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold?
Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Comparing STEP 2 ( Lancet , 2021) with…
|
+7 | 11 | 281 | 6mo |
|
Tirzepatide molecular mass and the charge states you would expect on ESI
Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited…
|
+36 | 40 | 44k | 11mo |
|
Tirzepatide's shorter half-life and its one practical consequence
On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…
|
+18 | 29 | 20k | 8mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…
|
+5 | 9 | 44k | 13mo |
|
The C-cell question: rodent findings and their human context
Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of a…
|
+41 | 45 | 24k | 12mo |
|
Journal club: FLOW and the renal composite, component by component
On the subject in the title: Journal club: FLOW and the renal composite, component by component Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…
|
+84 | 91 | 18k | 2y |
|
Revisiting: Food effects on oral incretin absorption: what is documented
Revisiting: Food effects on oral incretin absorption: what is documented — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read it before…
|
+6 | 10 | 51k | 13mo |
|
Comparing the STEP programme populations: who was actually enrolled
Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with FLOW ( N…
|
2 | 7.5k | 2mo |